Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results
- Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge
- Contineum announces topline data from PIPE-791 trial
- Contineum Therapeutics Announces Positive Phase 1b Trial Results
- 3 Best Stocks to Buy Now, 8/19/2025, According to Top Analysts